MCID: MYC005
MIFTS: 44

Myocardial Stunning malady

Categories: Cardiovascular diseases

Aliases & Classifications for Myocardial Stunning

Aliases & Descriptions for Myocardial Stunning:

Name: Myocardial Stunning 12 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9767
MeSH 42 D017682
UMLS 69 C0206146

Summaries for Myocardial Stunning

MalaCards based summary : Myocardial Stunning is related to myocardial infarction and ischemia, and has symptoms including asthenia, body temperature changes and cyanosis. An important gene associated with Myocardial Stunning is SLC9A1 (Solute Carrier Family 9 Member A1), and among its related pathways/superpathways are Vascular smooth muscle contraction and Folate Metabolism. The drugs Hydroxocobalamin and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include heart, neutrophil and skin, and related phenotypes are Negative genetic interaction between BLM-/- and BLM+/+ and cardiovascular system

Wikipedia : 71 In cardiology, stunned myocardium is a state when some section of the myocardium (corresponding to area... more...

Related Diseases for Myocardial Stunning

Diseases related to Myocardial Stunning via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 29.9 AGTR1 EDN1 SERPINC1 TNNI3 TNNT2
2 ischemia 10.4
3 cardiomyopathy 10.3
4 isolated brachycephaly 10.2 TNNI3 TNNT2
5 glomerulonephritis 10.2 TNNI3 TNNT2
6 central cord syndrome 10.2 KCNJ5 SOD1
7 eosinophilic pneumonia 10.1 AGTR1 TNNI3
8 mental retardation hypocupremia hypobetalipoproteinemia 10.1 AGTR1 SOD1
9 neurological manifestations of pompe disease 10.1 CAT SOD1
10 mosaic trisomy 1 10.1 TNNI3 TNNT2
11 retinitis pigmentosa 18 10.1 TNNI3 TNNT2
12 stickler sydrome, type i, nonsyndromic ocular 10.1 CAT SOD1
13 lupus erythematosus 10.1 SERPINC1 TNNI3 TNNT2
14 sialadenitis 10.1 AGTR1 EDN1
15 eastern equine encephalitis 10.1 AGTR1 EDN1
16 leukocyte disease 10.1 SERPINC1 TNNI3 TNNT2
17 intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.1 AGTR1 KCNJ5
18 aplasia cutis congenita recessive 10.1 AGTR1 EDN1
19 acute myocardial infarction 10.1
20 endotheliitis 10.1
21 sick sinus syndrome 1 10.1 KCNJ5 SLC9A1 TNNT2
22 coronary artery disease 10.0
23 artery disease 10.0
24 alpha-2-plasmin inhibitor deficiency 10.0 AGTR1 EDN1 SERPINC1
25 welander distal myopathy 10.0 AGTR1 EDN1 SERPINC1
26 petrositis 10.0 AGTR1 EDN1
27 neonatal diabetes mellitus 10.0 CAT EDN1
28 adult t-cell leukemia 9.9 EDN1 SERPINC1 TNNI3 TNNT2
29 ceroid lipofuscinosis, neuronal, 8 9.9 CAT EDN1 TNNT2
30 indeterminate leprosy 9.9 AHSP EDN1 TNNI3
31 lymphadenitis 9.9 AGTR1 EDN1
32 mucinous ovarian cystadenoma 9.9 CAT EDN1 SLC9A1 SOD1
33 pyrimidine metabolic disorder 9.9 AGTR1 EDN1 SERPINC1 TNNI3
34 aneurysm 9.9
35 hypoxia 9.9
36 cardiogenic shock 9.9
37 cardiac arrest 9.9
38 pulmonary edema 9.9
39 pericarditis 9.8 CAT EDN1 SERPINC1 SOD1
40 xanthogranulomatous pyelonephritis 9.7 AGTR1 EDN1 SOD3 TNNI3 TNNT2
41 cerebritis 9.7
42 coronary stenosis 9.7
43 kidney disease 9.7
44 hyperthyroidism 9.7
45 pheochromocytoma 9.7
46 peritonitis 9.7
47 pulmonary hypertension 9.7
48 status epilepticus 9.7
49 epilepsy 9.7
50 cervicitis 9.7

Graphical network of the top 20 diseases related to Myocardial Stunning:



Diseases related to Myocardial Stunning

Symptoms & Phenotypes for Myocardial Stunning

UMLS symptoms related to Myocardial Stunning:


asthenia, body temperature changes, cyanosis, edema, eye manifestations, fatigue, flushing, oral manifestations, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, skin manifestations, chills, polydipsia, renal colic, hot flushes, urological manifestations, mobility limitation, prodromal symptoms, hypertriglyceridemic waist, medically unexplained symptoms

GenomeRNAi Phenotypes related to Myocardial Stunning according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Negative genetic interaction between BLM-/- and BLM+/+ GR00255-A-1 8.92 EDN1 SOD3 TNNI3 TNNT2

MGI Mouse Phenotypes related to Myocardial Stunning:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 AGTR1 EDN1 KCNJ5 SERPINC1 SLC9A1 SOD1
2 homeostasis/metabolism MP:0005376 9.56 AGTR1 CAT EDN1 SERPINC1 SLC9A1 SOD1
3 mortality/aging MP:0010768 9.28 AGTR1 CAT EDN1 SERPINC1 SLC9A1 SOD1

Drugs & Therapeutics for Myocardial Stunning

Drugs for Myocardial Stunning (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
4
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
5
Ticagrelor Approved Phase 4 274693-27-5 9871419
6
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
8
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
9
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
10 Simendan Phase 4,Phase 2
11 Hematinics Phase 4
12 Trace Elements Phase 4
13 Vasodilator Agents Phase 4,Phase 2
14 Vitamin B 12 Phase 4
15 Vitamin B Complex Phase 4
16 Pharmaceutical Solutions Phase 4
17 Anti-Arrhythmia Agents Phase 4,Phase 2
18 Vitamins Phase 4
19 Phosphodiesterase Inhibitors Phase 4,Phase 2
20 Protective Agents Phase 4,Phase 2
21 Micronutrients Phase 4
22 Cardioplegic Solutions Phase 4
23 Adrenergic Agents Phase 4
24 Neurotransmitter Agents Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Autonomic Agents Phase 4
27 Calcium, Dietary Phase 4
28 Chlorhexidine gluconate Phase 4
29 Atorvastatin Calcium Phase 4 134523-03-8
30 Rosuvastatin Calcium Phase 4 147098-20-2
31 Analgesics Phase 4
32 calcium channel blockers Phase 4
33 Adrenergic Antagonists Phase 4
34 Adrenergic beta-1 Receptor Antagonists Phase 4
35 Adrenergic beta-Antagonists Phase 4
36 Sympatholytics Phase 4
37 Cyclooxygenase Inhibitors Phase 4
38 Analgesics, Non-Narcotic Phase 4
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
40 Hypolipidemic Agents Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Fibrinolytic Agents Phase 4
43 Anticholesteremic Agents Phase 4
44 Anti-Inflammatory Agents Phase 4
45 Antihypertensive Agents Phase 4
46 Purinergic P2 Receptor Antagonists Phase 4
47 Purinergic P2Y Receptor Antagonists Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4
49 Lipid Regulating Agents Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show all 16)
id Name Status NCT ID Phase
1 Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Unknown status NCT01500785 Phase 4
2 The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) Enrolling by invitation NCT02767401 Phase 4
3 Ranolazine a Potential New Therapeutic Application Not yet recruiting NCT02687269 Phase 4
4 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
5 Levosimendan Administration in Neonates With Transposition of the Great Arteries Completed NCT01120106 Phase 2
6 Serial Echocardiography After Subarachnoid Hemorrhage Unknown status NCT00123695
7 Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration Completed NCT02545426
8 Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome Completed NCT00586183
9 Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study) Completed NCT00213746
10 Exercise-induced Changes in Cardiac Function & Morphology Completed NCT01179802
11 Analysis of Heart Muscle Function Following Exercise in Patients With Heart Disease Completed NCT00001528
12 Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients Recruiting NCT02145260
13 Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy Enrolling by invitation NCT02930265
14 Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation. Not yet recruiting NCT02770183
15 Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients Not yet recruiting NCT02207153
16 Steroid-induced Reduction of Surgical Stress Study Withdrawn NCT00807521

Search NIH Clinical Center for Myocardial Stunning

Cochrane evidence based reviews: myocardial stunning

Genetic Tests for Myocardial Stunning

Anatomical Context for Myocardial Stunning

MalaCards organs/tissues related to Myocardial Stunning:

39
Heart, Neutrophil, Skin, Eye, Endothelial, Testes, Kidney

Publications for Myocardial Stunning

Articles related to Myocardial Stunning:

(show top 50) (show all 422)
id Title Authors Year
1
Doppler echocardiographic myocardial stunning index predicts recovery of left ventricular systolic function after primary percutaneous coronary intervention. ( 27543440 )
2016
2
Pentobarbital-Induced Myocardial Stunning in Status Epilepticus Requiring Extracorporeal Membrane Oxygenation: A Case Report and Literature Review. ( 27529037 )
2016
3
Parafascicular nucleus-heart neural crosstalk: Implications for seizure-induced myocardial stunning. ( 27539366 )
2016
4
Citric Acid Cycle Metabolites Predict the Severity of Myocardial Stunning and Mortality in Newborn Pigs. ( 27741040 )
2016
5
Hemodialysis-Induced Myocardial Stunning: A Review. ( 26290919 )
2015
6
Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest. ( 26275089 )
2015
7
CASE 0-2015 Problem-Solving in Transcatheter Aortic Valve Replacement: Cardiovascular Collapse, Myocardial Stunning, and Mitral Regurgitation. ( 26119409 )
2015
8
Reply to the letter "Post-ischemic myocardial stunning was the starting point of takotsubo syndrome: Restitution is justified after falling down on". ( 26285184 )
2015
9
Prevention of myocardial stunning during percutaneous coronary interventions: novel insights from pre-treatment with glucagon-like peptide-1. ( 25700753 )
2015
10
Acute intraoperative neurogenic myocardial stunning during intracranial endoscopic fenestration and shunt revision in a pediatric patient. ( 26314948 )
2015
11
Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia. ( 26419678 )
2015
12
Post-ischemic myocardial stunning was the starting point of takotsubo syndrome: Restitution is justified after falling down on. ( 26163910 )
2015
13
Isolated Pulmonary Edema without Myocardial Stunning in Brainstem Strokes. ( 26322335 )
2014
14
Seizure-Induced Myocardial Stunning: A Possible Cardiac Link to Sudden Unexpected Death In Epilepsy (SUDEP). ( 25305671 )
2014
15
Rare giant T-wave inversions associated with myocardial stunning: report of 2 cases. ( 25068953 )
2014
16
Myocardial stunning after resuscitation from cardiac arrest following spinal anaesthesia. ( 24963188 )
2014
17
Clinical characteristics of myocardial stunning in acute stroke. ( 25022725 )
2014
18
Reversible T-Wave Inversions and Neurogenic Myocardial Stunning in a Patient with Recurrent Stress-Induced Cardiomyopathy. ( 24147830 )
2013
19
Cardiomyocyte-specific overexpression of an active form of Rac predisposes the heart to increased myocardial stunning and ischemia-reperfusion injury. ( 23161879 )
2013
20
High-dose erythropoietin during cardiac resuscitation lessens postresuscitation myocardial stunning in swine. ( 23806450 )
2013
21
Takotsubo and Takotsubo-like syndrome: a common neurogenic myocardial stunning pathway? ( 23058349 )
2013
22
Myocardial bridging, apical ballooning syndrome and myocardial stunning: shall we connect the dots? ( 23647592 )
2013
23
Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine. ( 22994851 )
2013
24
N-terminal Pro-B-type natriuretic peptide and its correlation to haemodialysis-induced myocardial stunning. ( 23880872 )
2013
25
CMR imaging for the evaluation of myocardial stunning after acute myocardial infarction: a meta-analysis of prospective trials. ( 23575990 )
2013
26
Spontaneous coronary artery dissection triggered post-ischemic myocardial stunning and takotsubo syndrome: two different names for the same condition. ( 23273747 )
2013
27
Hot shot induction and reperfusion with a specific blocker of the es-ENT1 nucleoside transporter before and after hypothermic cardioplegia abolishes myocardial stunning in acutely ischemic hearts despite metabolic derangement: hot shot drug delivery before hypothermic cardioplegia. ( 23422047 )
2013
28
Pathophysiology and pathogenesis of post-resuscitation myocardial stunning. ( 21584712 )
2012
29
Postischemic myocardial stunning is superior to transient ischemic dilation for detecting multivessel coronary artery disease. ( 22185710 )
2012
30
Nitric oxide has no obligatory role in isoflurane late preconditioning against myocardial stunning. ( 23044225 )
2012
31
Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. ( 22822013 )
2012
32
Comparative assessment of rest and post-stress left ventricular volumes and left ventricular ejection fraction on gated myocardial perfusion imaging (MPI) and echocardiography in patients with transient ischaemic dilation on adenosine MPI: myocardial stunning or subendocardial hypoperfusion? ( 22565241 )
2012
33
Isoflurane late preconditioning against myocardial stunning is associated with enhanced antioxidant defenses. ( 22103751 )
2012
34
Huge negative T waves reaching a depth of 36 mm below the isoelectric line on ECG associated with myocardial stunning. ( 22126257 )
2012
35
Non-invasive ventilation for severe TRALI and myocardial stunning: report and literature review. ( 22869453 )
2012
36
Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient. ( 22851961 )
2012
37
Inhalation of hydrogen gas protects against myocardial stunning and infarction in swine. ( 22263852 )
2012
38
Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? ( 22297544 )
2012
39
Distinct effects of acute pretreatment with lipophilic and hydrophilic statins on myocardial stunning, arrhythmias and lethal injury in the rat heart subjected to ischemia/reperfusion. ( 22106818 )
2011
40
Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). ( 21597028 )
2011
41
Dialysis-induced myocardial stunning: the other side of the cardiorenal syndrome. ( 21546884 )
2011
42
Individualised dialysate temperature improves intradialytic haemodynamics and abrogates haemodialysis-induced myocardial stunning, without compromising tolerability. ( 21346338 )
2011
43
Peritoneal dialysis is not associated with myocardial stunning. ( 20522673 )
2011
44
Complex I syndrome in myocardial stunning and the effect of adenosine. ( 21723387 )
2011
45
Early detection of myocardial stunning using low-dose dobutamine magnetic resonance imaging. ( 21402349 )
2011
46
Reversible myocardial stunning due to carbon monoxide exposure. ( 21556453 )
2011
47
Investigation of myocardial stunning after cardiopulmonary resuscitation in pigs. ( 21565687 )
2011
48
Contractile reserve and extent of transmural necrosis in the setting of myocardial stunning: comparison at cardiac MR imaging. ( 20392984 )
2010
49
Head to head comparison of quantitative versus visual analysis of contrast CMR in the setting of myocardial stunning after STEMI: implications on late systolic function and patient outcome. ( 20174969 )
2010
50
Coronary microcirculation changes during myocardial stunning in dogs. ( 20924181 )
2010

Variations for Myocardial Stunning

Expression for Myocardial Stunning

Search GEO for disease gene expression data for Myocardial Stunning.

Pathways for Myocardial Stunning

GO Terms for Myocardial Stunning

Cellular components related to Myocardial Stunning according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 myofibril GO:0030016 9.32 TNNI3 TNNT2
2 T-tubule GO:0030315 9.26 KCNJ5 SLC9A1
3 troponin complex GO:0005861 9.16 TNNI3 TNNT2
4 cardiac myofibril GO:0097512 8.96 TNNI3 TNNT2
5 cardiac Troponin complex GO:1990584 8.62 TNNI3 TNNT2

Biological processes related to Myocardial Stunning according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.77 CAT EDN1 SOD3
2 response to oxidative stress GO:0006979 9.67 CAT SOD1 SOD3
3 response to drug GO:0042493 9.67 CAT EDN1 SLC9A1 SOD1
4 response to activity GO:0014823 9.62 CAT EDN1
5 cardiac muscle contraction GO:0060048 9.62 TNNI3 TNNT2
6 muscle filament sliding GO:0030049 9.61 TNNI3 TNNT2
7 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway GO:0051482 9.61 AGTR1 EDN1
8 regulation of sensory perception of pain GO:0051930 9.6 EDN1 SLC9A1
9 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.58 TNNI3 TNNT2
10 regulation of vasoconstriction GO:0019229 9.58 AGTR1 EDN1
11 superoxide metabolic process GO:0006801 9.57 SOD1 SOD3
12 regulation of pH GO:0006885 9.56 EDN1 SLC9A1
13 positive regulation of cardiac muscle hypertrophy GO:0010613 9.55 EDN1 SLC9A1
14 regulation of muscle contraction GO:0006937 9.54 TNNI3 TNNT2
15 response to muscle stretch GO:0035994 9.52 EDN1 SLC9A1
16 response to reactive oxygen species GO:0000302 9.51 CAT SOD1
17 cellular response to oxidative stress GO:0034599 9.5 CAT SOD1 SOD3
18 response to copper ion GO:0046688 9.48 SOD1 SOD3
19 superoxide anion generation GO:0042554 9.46 EDN1 SOD1
20 heart contraction GO:0060047 9.43 SOD1 TNNI3
21 removal of superoxide radicals GO:0019430 9.4 SOD1 SOD3
22 negative regulation of ATPase activity GO:0032780 9.26 TNNI3 TNNT2
23 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.16 SLC9A1 TNNI3
24 hemoglobin metabolic process GO:0020027 8.96 AHSP CAT
25 response to ozone GO:0010193 8.62 CAT EDN1

Molecular functions related to Myocardial Stunning according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase 2B binding GO:0030346 9.26 SLC9A1 SOD1
2 superoxide dismutase activity GO:0004784 9.16 SOD1 SOD3
3 troponin C binding GO:0030172 8.96 TNNI3 TNNT2
4 antioxidant activity GO:0016209 8.8 CAT SOD1 SOD3

Sources for Myocardial Stunning

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....